Prognostic impact of number of examined lymph nodes on survival of patients with appendiceal neuroendocrine tumors

Table 3 The 3-, 5-, and 10-yr cancer-specific survival rates for patients

Patients	3-yr, %	5-yr, %	10-yr, %	Follow-up, mo	Median follow-up, mo	Median survival time, mo
All	91.2	87.5	81.7	0-499	31	-
Stage I	99.7	99.7	-	0-83	23	-
Stage II	98.7	95.5	-	0-83	42	-
Stage III	89.0	82.0	-	0-82	38	-
Stage IV	42.0	25.1	-	0-83	23	30

Median survival is unavailable when there were not half patients dead at the cutoff date.